Introduction {#sec1-1}
============

Central venous catheters (CVCs) are routinely utilized in health care industries, primarily in critically care units.\[[@ref1]\] CVC is a device that is temporarily placed into patients for assessing the central veins. It is also known as lines.\[[@ref2][@ref3]\] CVCs can be used for monitoring hemodynamic status, administration of parental nutrition, blood and blood products,\[[@ref2][@ref3]\] medications or chemotherapy drugs, and performing of hemodialysise ct. when it is not safe to administer through peripheral venous catheters.\[[@ref4][@ref5]\]

Presently, four types of CVCs commonly used are tunneled (e.g. Hickman\'s Catheters), non-tunneled catheter, peripherally inserted central catheters (PICCs), and totally implantable port or totally implantable venous access devices.\[[@ref5][@ref6]\]

CVCs are having great use in critical care units and associated with decrease stay of hospitalizations, enhance the patient\'s safety, and reduction of the hospitalization costs.\[[@ref7][@ref8]\] However, CVCs are associated with complications. Complications related to CVCs can be mechanical complications, which occur at the time of insertion such as hematoma, arterial puncture; pneumothorax, etc., ranges from 5% to 29%\[[@ref9][@ref10]\] and complications related to infections ranges from 5% to 26% and complications related to thrombosis ranges from 2% to 26%.\[[@ref10][@ref11]\]

CVCs obstruction may lead to venous thrombosis or develop a fibrin sheath, accounts approximately 40% of catheter-related complications, which are major causes for catheter dysfunctions.\[[@ref12]\] Occlusion of catheter can be categorized as partial (able to flush freely but not able to aspirate the blood) and complete (not able to flush freely and aspirate blood).\[[@ref13][@ref14]\]

There are various factors like condition of patient, lumen size and position of catheter, insertion site and technique, chemical composition and nature of flushing solution, etc., which are associated with catheter-related thrombosis.\[[@ref15]\] Catheter-related thrombosis is an important causative factor for not only morbidity and mortality but also that thrombus acts as a medium for micro-organism growth.\[[@ref16]\] Another complication which is associated with CVC-related upper limb DVT is pulmonary embolism, which is a life-threatening situation, occurs near about 15% of patients.\[[@ref17]\]

Therefore, to prevent the risk of catheter occlusion, it is very much needed for maintaining patency and prolong functioning of the catheter,\[[@ref18][@ref19]\] and to achieve it proper flushing of catheter is deemed necessary and considered as primary intervention.\[[@ref20][@ref21]\] To prevent or avoid formation of thrombus in CVCs, the solutions used by clinician to flush the catheter include heparin, 0.9% sodium chloride, vitamin C, lepirudin, sodium citrate, polygelin,\[[@ref22][@ref23]\] alteplase, or urokinase.\[[@ref24]\]

Heparin flushing has been used and most commonly performed procedure to avoid thrombus formation in CVCs.\[[@ref25]\] Heparin flush is the standard guideline to maintain the patency of CVCs.\[[@ref26][@ref27][@ref28]\] However, the effectiveness of this standard practice is still unproven\[[@ref29]\] and associated with some complications such as heparin-induced thrombocytopenia (HIT), allergy, and risk of bleeding.\[[@ref30][@ref31][@ref32]\]

It is reported by some studies that utilization of normal saline is as much effective as heparin to maintain the patency of CVC.\[[@ref33][@ref34][@ref35]\] Furthermore, two Cochrane systematic reviews provided inconclusive evidence favoring the application of heparin solution over normal saline for maintaining the patency of central venous and arterial catheters.\[[@ref36][@ref37]\]

As such, a number of studies with conflicting results have been published, prompting further debate on which solution is better for CVC maintenance. Therefore, this systematic review and metaanalysis of RCTs was carried out to assess more precisely the effectiveness of heparin in maintaining CVCs when compared with normal saline.

Materials and Methods {#sec1-2}
=====================

We followed PRISMA guidelines for this systematic review and meta-analysis \[[Additional file 1](#App1){ref-type="app"}\]. The PICO framework was utilized to address the review question evidently \[[Additional file 2](#App2){ref-type="app"}\]. The primary outcome for this review was catheter patency, and secondary outcomes were catheter-related infection, venous thrombosis, HIT, bleeding, and mortality.

Study selection {#sec2-1}
---------------

There were two independent reviewers who read the title and abstract and wherever needed the full text of applicable or probably related references, to select studies which required being more detail examination. When there was any variation of opinions between both reviewers, then first author was consulted to make final conclusion for the study. We also tried to contact the authors of ongoing trials and whose studies needed more clarification. In this review, we included randomized controlled trials (RCTs) compared the efficacy of heparin flush versus normal saline flush to maintain the patency of CVC in adult patients and published in English language only. Studies were excluded when primary researcher uses other methods of randomization like quasi randomization, studies on non-human, case-control, cohort studies, letters and reviews, and age of participants \<18 years of age.

Search strategy {#sec2-2}
---------------

Review authors screened the Cochrane library l (last search 31 December 2018). We also searched MEDLINE (Ovid, 2012 to 2018), Embase (Ovid, 2012 to 2018), and clinical trials registers (last search 31 December 2018). We used free-text terms and MeSH terms like CVC, heparin, normal saline, sodium chloride, RCT, catheterization, flushing and patency, etc., \[[Additional file 3](#App3){ref-type="app"}\] for searching the studies. We explored all articles related to present review and also used list of references from searched published studies to identify new relevant studies.

Data extraction {#sec2-3}
---------------

There were two reviewers who extracted data and discussed with the third reviewer, who then solved the discrepancies. Data regarding the first author, publication year, country, study type, population, interventions (doses of heparin) outcomes (Primary and Secondary outcomes), and results were extracted. Whenever, it was required to get additional information, we approached the authors of those studies.

Assessment of bias {#sec2-4}
------------------

Risks of bias of studies were evaluated by two authors independently. Evaluation of risk bias was done by using standard guidelines of Cochrane. If there was any discrepancy between two authors, then the third reviewer was consulted to get the final judgment. Risk of bias comprised of random sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting it was assessed by using funnel plot \[[Figure 1](#F1){ref-type="fig"}\], and other bias.

![Funnel plot](JFMPC-8-2779-g001){#F1}

Types of outcome {#sec2-5}
----------------

In the included studies, the primary outcomes of interest communicated were maintaining the patency and occlusion of CVC. Secondary outcomes were HIT, risk of bleeding or hemorrhage from any part in the body, infection and thrombosis related to CVC, allergic reaction to heparin, cost of treatment with heparin, and mortality.

Data analysis {#sec2-6}
-------------

Statistical analysis was done as per the statistical guidelines protocol in the current version of the Cochrane Handbook for Systematic Review of Randomized controlled trial. RevMan Manager 5 was used for review production and data analysis. Studies which assessed the effects of heparin flush to maintain the patency of CVC were analyzed for subgroups and secondary outcomes. There were three different types of unit for analysis: six studies (participants), two studies (catheters), and two studies (line access). In this present review, we utilized risk ratio (RR) for dichotomous data. The mean ± standard deviations (SD) were used to express the continuous data and analyzed using standard mean differences (SMDs). As I^2^ values were low, which indicates heterogeneity is low. Hence, we are supposed to use fixed-effect model to pool data. However, we planned and used random-effect model (for continuous data) because although the same medication was used to flush or lock the CVC in all studies (heparin), we identified fairly heterogeneity in the study methods involved like different types of patients, distinct settings, dissimilar duration of follow-up, inconsistent amount of concentration of drug (heparin), etc. The fixed model (MantelHaenszel) was used for dichotomous data. The publication bias was assessed by using funnel plot.

Results {#sec1-3}
=======

Study selection and characteristics {#sec2-7}
-----------------------------------

We followed PRISMA guidelines for search and selection of studies, which met the inclusion criteria \[[Figure 2](#F2){ref-type="fig"}\]. Total 1,157 records were searched through electronic database. Out of them, 762 were found as duplicates because of overlap of the database, remaining 395 references were screened and 357 records were found not relevant and excluded. Further,\[[@ref38]\] full-text articles were assessed for eligibility and 29 of them were excluded because they did not meet the inclusion criteria. Finally, there are nine studies which met the pre-specified inclusion criteria and included for systematic review and meta-analysis.

![Selection of studies as per PRISMA guideline \[ICTRP = International Clinical Trials Registry Platform (WHO database)\]](JFMPC-8-2779-g002){#F2}

Baseline characteristics {#sec2-8}
------------------------

In total, nine studies were included which originated from Belgium\[[@ref39]\] (*n* = 1), Iran\[[@ref40][@ref41][@ref42]\] (*n* = 3), India\[[@ref43]\] (*n* = 1), Italy\[[@ref44]\] (*n* = 1), and USA\[[@ref45][@ref46][@ref47]\] (*n* = 3) and from those studies, only one study\[[@ref44]\] was conducted at multi-centric level, remaining 8 studies were single centric. The concentration of heparin ranged from 10 IU/ml to 1000 IU/ml. The duration of follow-up varied from 1 day to 204 days and 1 day to 294 days in normal saline (NS) group and heparin group, respectively. There were only three studies\[[@ref40][@ref41][@ref42][@ref43][@ref44][@ref45][@ref46]\] which carried out in non-ICUs setting, whereas remaining six were performed in critical care units, and all studies were reported from 2012 to 2018. The basic characteristics of included studies were presented in [Table 1](#T1){ref-type="table"}.

###### 

Basic characteristics of included studies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID                                             Study design          Participants                                             Intervention                                                                            Results
  ---------------------------------------------------- --------------------- -------------------------------------------------------- --------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Beigi 2014, Iran (S)                                 Single-blinded, RCT   129 patients with chronic kidney disease\                1000 IU heparin Versus 0.9% saline solution                                             Catheter thrombosis
                                                                             *n*=100 randomized\                                                                                                                              
                                                                             *n*=50 NS group\                                                                                                                                 
                                                                             *n*=50 heparin group                                                                                                                             

  No one in both groups                                                                                                                                                                                                       

  Required manipulation to maintain patency                                                                                                                                                                                   

  Heparin group=2 (4.2%) 0.9% NS group=3 (6.1%)                                                                                                                                                                               

  Bleeding experience                                                                                                                                                                                                         

  Heparin group=4 (8.5%) 0.9% NS group=3 (6.1%)                                                                                                                                                                               

  Dal Molin 2015, Italy (M)                            RCT , Open Label      430 patient with cancer Randomized\                      Normal saline solution versus heparin 5 cc (50I U/ml)                                   Withdrawal occlusion
                                                                             *n*=203 NS group\                                                                                                                                
                                                                             *n*=212 Heparin group                                                                                                                            

  Heparin group=10 (4.71%)                                                                                                                                                                                                    

  NS group=14 (6.90%)                                                                                                                                                                                                         

  Total occlusion                                                                                                                                                                                                             

  Heparin group=0 (00%)                                                                                                                                                                                                       

  NS group=1 (.49%)                                                                                                                                                                                                           

  Infection                                                                                                                                                                                                                   

  Heparin group=1 (0.49%)                                                                                                                                                                                                     

  NS group=1 (0.49%)                                                                                                                                                                                                          

  Venous thrombosis and Extravasation                                                                                                                                                                                         

  Heparin group=1 (0.49%)                                                                                                                                                                                                     

  NS group=0 (00%)                                                                                                                                                                                                            

  Goossens, 2013, Belgium (S)                          RCT , Open Label      802 patient with cancer Randomized\                      Normal saline solution versus\                                                          Easy injection, impossible aspiration incidence
                                                                             *n*=398 NS group\                                        Heparin 3 ml (100 IU/ml)                                                                
                                                                             *n*=404 Heparin group                                                                                                                            

  Heparin group=3.92%                                                                                                                                                                                                         

  NS group=3.70%                                                                                                                                                                                                              

  Catheter-related blood stream infection                                                                                                                                                                                     

  Heparin group=0.10/1000 catheter days                                                                                                                                                                                       

  NS group=0.03/1000 catheter days                                                                                                                                                                                            

  Heidari, 2015, Iran (S)                              Double Blind, RCT     802 patient with various diseases Randomized\            Normal saline solution versus\                                                          Duration of CVC flushing
                                                                             *n*=42 NS group\                                         Heparin 3 ml (100 IU/ml)                                                                
                                                                             *n*=42 Heparin group                                                                                                                             

  Heparin group=15.47±3.9                                                                                                                                                                                                     

  NS group=14.45±5.56                                                                                                                                                                                                         

  Taking blood from CVC                                                                                                                                                                                                       

  Heparin group=15.23±4.09                                                                                                                                                                                                    

  NS group=13.8±5.94                                                                                                                                                                                                          

  Kiein, 2018, Florida (S)                             RCT, Open Label       30 patients with cancer (698 observations) Randomized\   Standard Flush (NS+Heparin) 10 or 1000 IU/ml versus Normal saline                       Rate of patency of CVC Standard group=313 (91%) NS group=325 (92%) Use of tPA Standard group=06 (25%) NS group=07 (27%) Occurrence of CLABSI Standard group=00 NS group=01
                                                                             *n*=15 NS group\                                                                                                                                 
                                                                             *n*=15 Heparin group                                                                                                                             

  Lyons, 2014, USA (S)                                 RCT, Single Blinded   90 patients without cancer randomized\                   Normal Saline versus Heparin (High) heparin 3 ml (100 IU/ml) Heparin 5 ml (100 IU/ml)   Rate of occlusion of catheter
                                                                             *n*=30 NS group\                                                                                                                                 
                                                                             *n*=30 SASH (High)\                                                                                                                              
                                                                             *n*=30 SASH (low)                                                                                                                                

  Heparin (High) = 9 (32.2%)                                                                                                                                                                                                  

  Heparin (Low) = 8 (26.7%)                                                                                                                                                                                                   

  NS group=9 (32.2%)                                                                                                                                                                                                          

  Catheters needed alteplase                                                                                                                                                                                                  

  SASH (High) = 3 (9.4%)                                                                                                                                                                                                      

  SASH (Low) = 3 (10.0%)                                                                                                                                                                                                      

  NS group=7 (25.0%)                                                                                                                                                                                                          

  Mahesh, 2014, India (S)                              RCT, Open Label       100 patients with respiratory disease\                   0.9% NS solution versus Heparin 3 ml (10 IU/ml)                                         Non-patency of CVC
                                                                             *n*=50 NS group\                                                                                                                                 
                                                                             *n*=50 Heparin group                                                                                                                             

  Heparin group=2 (4%)                                                                                                                                                                                                        

  NS group=4 (8%)                                                                                                                                                                                                             

  Thrombocytopenia                                                                                                                                                                                                            

  No incidence in both group                                                                                                                                                                                                  

  Schallom, 2012, St. Louis (S)                        RCT, Open Label       341 patient with various diseases 295 pt. randomized\    0.9% NS solution versus Heparin 3 ml (10 IU/ml)                                         Lumen non-patency
                                                                             *n*=150 NS group\                                                                                                                                
                                                                             *n*=145 heparin group                                                                                                                            

  Heparin group=12 (3.8%)                                                                                                                                                                                                     

  NS group=25 (6.3%)                                                                                                                                                                                                          

  Rate of heparin-induced thrombocytopenia                                                                                                                                                                                    

  Same between groups                                                                                                                                                                                                         

  Catheter-related blood Stream infection                                                                                                                                                                                     

  Similar in both groups                                                                                                                                                                                                      

  Ziyaeifard, 2015, Iran (S)                           RCT, Double-blinded   100 patients with cardiac surgery Randomized\            NS solution versus heparin 5 ml (10 IU/ml)                                              CVC occlusion
                                                                             *n*=50 NS group\                                                                                                                                 
                                                                             *n*=50 Heparin group                                                                                                                             

  No occlusion in both groups                                                                                                                                                                                                 

  Catheter manipulation and displacement (3^rd^ day)                                                                                                                                                                          

  Heparin group=14 (28%)                                                                                                                                                                                                      

  NS group=17 (34%)                                                                                                                                                                                                           
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

S=Single center; M=Multi-centers; NS=Normal saline; RCT=Randomized control trial

Methodological quality {#sec2-9}
----------------------

Most of the studies expressed a low or unclear level of risk of bias, except in performance and detection bias as display in [Figure 3](#F3){ref-type="fig"}. There were only two studies\[[@ref43][@ref45]\] that did not clearly explain about method of randomization. In terms of allocation concealment, 4 trials\[[@ref39][@ref44][@ref46][@ref47]\] discussed properly, whereas the remaining 5 trials were unclear about this. Furthermore, there were only two studies\[[@ref41][@ref42]\] reported an appropriate method of blinding, one trial\[[@ref46]\] was unclear and remaining all others have high risk for performance and detection bias. With regard to incomplete outcome data, only one study\[[@ref39]\] had unclear risk, remaining others described drop-out information. In terms of selective reporting, only one study\[[@ref43]\] had high risk of reporting bias, and three\[[@ref40][@ref41][@ref47]\] were unclear risk and remaining low risk as they reported as per pre-specified protocols. There were five studies\[[@ref40][@ref41][@ref42][@ref44][@ref46]\] which had a small sample size. The risk of bias was presented in Figure [3a](#F3){ref-type="fig"} and [b](#F3){ref-type="fig"}.

![(a) Risks of bias graph. (b) Risks of bias summary](JFMPC-8-2779-g003){#F3}

Meta-analysis {#sec2-10}
-------------

We identified nine eligible studies for present review and meta-analysis with a total number of 3,113 participants with different disease conditions. We identified variation in methods used by the included trials and difference in heparin strength (10 to 1000 IU/mL), duration of follow-up (1 to 294 days), participants with disease (participants with cancer or without cancer), and the unit of analysis which was used (participants, catheter, and catheter line access).

Consolidated results from eight studies (six studies used participants as unit of analysis with 1,622 participants and two studies used catheter as unit of analysis with 1,407 catheters) conveyed little favorable effect to maintain patency of CVC with heparin when compared with normal saline as evident by RR 0.83, 95% CI 0.50 to 1.40; *P* = 0.13.

We performed subgroup analysis on the basis of unit of analysis. When we used participants (1,622 participants from six studies) as unit of analysis, results reveal little favorable effect to maintain CVC patency with heparin than NS (RR 0.76, 95% CI 0.52 to 1.12; *P* = 0.16), whereas subgroup analysis was performed to use catheter as the unit of analysis exhibit no clear difference in maintaining patency of CVC between heparin and NS (RR 0.83, 95% CI 0.50 to 1.40; *P* = 0.49; 1407 catheters of two studies). When we used line access as unit of analysis, results reveal no clear difference in CVC patency between heparin and NS (RR 1.08, 95% CI 0.84 to 1.40; one study) [Figure 4](#F4){ref-type="fig"}.

![Forest plot of comparison between normal saline (NS) vs. heparin flush and the patency of catheter](JFMPC-8-2779-g004){#F4}

We also carried out subgroup analysis on the basis of kinds of participants, numbers of lumens, and strength of heparin concentration and duration of follow-up. We found no clear difference in catheter patency between participants without cancer and those with cancer (test for subgroup difference *P* = 0.72), and subgroup analysis to identify relationship between number of lumen (one lumen and two or more lumen) and catheter patency showed no clear difference between both group (test for subgroup difference *P* = 0.79). While subgroup analysis was performed between catheter patency and heparin strength (less or more than 1000 IU/ml) showed little difference. As less than 100IU/ml strength showed little favor to maintain patency (test for subgroup difference *P* = 0.47). Finally, we did analysis to detect the effect of follow-up duration and catheter patency and found that less than one-month follow-up had favorable effect when compared with the duration of follow-up was more than one-month (test for subgroup difference *P* = 0.23).

We studied to assess the difference of duration of CVC patency in three studies with 886 participants and 709 catheters and results reveal that there were no clear differences in duration of CVC patency between heparin and NS \[Mean Difference (MD) 0.42 days, 95% CI --0.21 to 1.01; *P* = 0.16\].

We also carried out analysis for secondary outcomes, and results show that except HIT, which was assessed in two studies with 395 participants showed there is no clear difference in the following outcomes: infection related to CVC in two studies with 1,097 participants (RR 0.74, 95% =0.03 to 19.54; *P* = 0.86), bleeding from any site in the body in three studies with 1,197 participants (RR 0.62, 95% =0.03 to 12.87; *P* = 0.76), CVC related thrombosis in three studies with 1,527 participants (RR 1.25, 95% =0.77 to 2.03; *P* = 0.37) and mortality in one study with 802 participants (RR 0.73, 95% =0.42 to 1.27; *P* = 0.26). Only one secondary outcome (HIT) in two studies with 395 participants show the contradictory effect with heparin (less cases of HIT in heparin group than NS group; RR 0.21, 95% =0.01 to 4.27; *P* = 0.31) [Figure 5](#F5){ref-type="fig"}.

![Forest plot of comparison between normal saline (NS) vs. heparin flush and secondary outcomes](JFMPC-8-2779-g005){#F5}

We downgraded the quality of evidence because of mainly unclear allocation concealment, imprecision, and doubt of publication bias.

Discussion {#sec1-4}
==========

CVC is used in clients with critical illness for the prevention of infection, injection of medications, and parenteral nutrition. Nurses along with other health care workers deal with such patients as a part of daycare routine, and if prevention of infection is done at an early stage, then it can reduce the risk of lung infection and other serious complication. Heparin and normal saline flush is used to keep the tubing patent until the administration of next medication and speedy recovery happens if used cautiously as primary prevention.

The use of CVC is common in critical care units for various purposes, but it is associated with some complications.\[[@ref1][@ref2][@ref4]\] One of the major complications is catheter occlusion, and heparin is a widely used solution to prevent occlusion of catheter.\[[@ref10][@ref11]\] However, complications such as allergic reaction, risk of bleeding, and HIT are associated with heparin flush.\[[@ref25][@ref30][@ref31]\] While some studies provided evidence that NS is as effective as heparin for maintaining CVC patency and have some potential benefits like less complication and cost than heparin.\[[@ref33][@ref34]\]

Therefore, the present review is carried out to identify which solution is better than other and results of our study revealed that heparin flush had a little favorable effect to maintain the patency of CVC when compared with NS, but there was no clear evidence of an effect on secondary outcomes between the groups.

There are few RCTs which compared heparin flush vs. normal saline flush for maintaining the patency of catheter in adults. One of the studies concluded that heparin was better than normal saline particularly in terms of catheter survival rate.\[[@ref22]\] While some other studies showed that there is no difference in patency of catheter when heparin was compared with normal saline.\[[@ref39][@ref40]\] Another report from a multicenter RCT\[[@ref43]\] consisted with\[[@ref39][@ref40]\] and concluded that heparin is not more effective than normal saline for maintaining CVCs patency, and there was no statistical difference was present.

Results of our review and meta-analysis are consistent with other reviews,\[[@ref2][@ref3]\] explained that heparin was associated with fewer occlusion rate of CVC than NS, but quality of evidence was very low. They also concluded that there was no evidence of differences in secondary outcomes (infection, bleeding, thrombosis, HIT, and mortality).

The results of other reviews\[[@ref36][@ref46]\] concluded that there is no evidence of a difference between the groups to maintain the patency of CVC. Another meta-analysis\[[@ref47]\] revealed that there is no evidence of different effectiveness between heparin flushing and normal saline or other solutions in reducing catheter occlusion.

There are some systematic reviews that used heparin in CVCs but have different inclusion and/or exclusion criteria from this review as one review\[[@ref48]\] was carried out among adults and pediatrics participants and concluded that there was a trend toward a decrease in catheter and venous thrombosis significantly when heparin is used. Another review\[[@ref49]\] in adults participants with CVCs or PICCs and compared heparin locking, continuous heparin perfusion, NS locking, and urokinase locking versus any other protocol, concluded that there is clear evidence that heparin is more effective than NS. Furthermore, two similar systematic reviews\[[@ref5][@ref50]\] carried out in pediatrics and concluded that it is still unclear whether heparin is required to maintain the patency of CVCs.

There are various factors like types of catheter, strength, amount, and frequency of heparin used for flushing, physical condition of patient, and puncture site that are associated with patency of CVC.\[[@ref51][@ref52]\] Therefore, well-designed RCTs are required to identify the effect of these factors on the primary outcome.

We found some potential limitations in this review. First, although there was low statistically heterogeneity but methodological heterogeneity likes different kinds of participants, use different strength of heparin concentration, and duration of follow-up in included studies. Second, we explored MEDLINE, Embase, and Cochrane library but could not search CINHAL. In this review, most of the included studies were single centric and had a small sample size.

Conclusion {#sec1-5}
==========

As per the evidence of this review, there is little or no effect of heparin to maintain patency of catheter when compared with normal saline but no clear evidence between heparin and normal saline flush in secondary outcomes. Moreover, the quality of evidence was very low; therefore, we are not sure whether heparin flush is better to maintain CVC patency than NS flush and results should be comprehended with cautiously. Therefore, further, it is needed to carry out large scale RCTs with standard methodology and at a multi-centric level to produce clear evidence which solution is better in terms of maintaining the patency, cost-effectiveness, and safety of the patients.
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###### 

PRISMA 2009 Checklist

  Section/topic                        \#   Checklist item                                                                                                                                                                                                                                                                                                Reported on page \#
  ------------------------------------ ---- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------
  **TITLE**                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                          
  Title                                1    Identify the report as a systematic review, meta-analysis, or both.                                                                                                                                                                                                                                           1
                                                                                                                                                                                                                                                                                                                                                          
  **ABSTRACT**                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                          
  Structured summary                   2    Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.   1
                                                                                                                                                                                                                                                                                                                                                          
  **INTRODUCTION**                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                          
  Rationale                            3    Describe the rationale for the review in the context of what is already known.                                                                                                                                                                                                                                1
  Objectives                           4    Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).                                                                                                                                                    3 Additional file 2
                                                                                                                                                                                                                                                                                                                                                          
  **METHODS**                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                          
  Protocol and registration            5    Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.                                                                                                                                 Not applicable
  Eligibility criteria                 6    Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.                                                                                                        2
  Information sources                  7    Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.                                                                                                                                    2
  Search                               8    Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.                                                                                                                                                                                 2, Additional file 3
  Study selection                      9    State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).                                                                                                                                                     2
  Data collection process              10   Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.                                                                                                                                    2
  Data items                           11   List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.                                                                                                                                                                         Additional file 2
  Risk of bias in individual studies   12   Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.                                                                                        2,5
  Summary measures                     13   State the principal summary measures (e.g., risk ratio, difference in means).                                                                                                                                                                                                                                 4
  Synthesis of results                 14   Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2^) for each meta-analysis.                                                                                                                                                       4
  Risk of bias across studies          15   Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).                                                                                                                                                                  2,5
  Additional analyses                  16   Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.                                                                                                                                                              6,7
                                                                                                                                                                                                                                                                                                                                                          
  **RESULTS**                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                          
  Study selection                      17   Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.                                                                                                                                               3 Figure-1
  Study characteristics                18   For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.                                                                                                                                                                  4,5 Table 1
  Risk of bias within studies          19   Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).                                                                                                                                                                                                     5 Figure 2 (2 (a), 2 (b))
  Results of individual studies        20   For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.                                                                                                      6,7 Figure 4 and 5
  Synthesis of results                 21   Present results of each meta-analysis done, including confidence intervals and measures of consistency.                                                                                                                                                                                                       6,7 Figure 4 and 5
  Risk of bias across studies          22   Present results of any assessment of risk of bias across studies (see Item 15).                                                                                                                                                                                                                               Figure 3
  Additional analysis                  23   Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression \[see Item 16\]).                                                                                                                                                                                       7
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  Summary of evidence                  24   Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).                                                                                                                          7
  Limitations                          25   Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).                                                                                                                                                 8
  Conclusions                          26   Provide a general interpretation of the results in the context of other evidence, and implications for future research.                                                                                                                                                                                       8
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###### 

PICO FRAMEWORK

  -------------- ------------------------------------------------------------------------------------------------------------------------------------------------------
  Population     Adult patients with central venous catheter
  Intervention   Heparin solution (any strength) for flushing the catheter
  Comparison     0.9% sodium chloride for flushing the catheter
  Outcome        Primary- catheter patency Secondary- catheter-related infection, venous thrombosis, bleeding from any site in the body, HIT, allergy, mortality etc.
  -------------- ------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Search strategy

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ("central venous catheters"\[MeSH Terms\] OR ("central"\[All Fields\] AND "venous"\[All Fields\] AND "catheters"\[All Fields\]) OR "central venous catheters"\[All Fields\] OR ("central"\[All Fields\] AND "venous"\[All Fields\] AND "catheter"\[All Fields\]) OR "central venous catheter"\[All Fields\]) AND ("heparin"\[MeSH Terms\] OR "heparin"\[All Fields\]) AND ("2012/01/01"\[PDAT\] : "2018/12/31"\[PDAT\])
  ("central venous catheters"\[MeSH Terms\] OR ("central"\[All Fields\] AND "venous"\[All Fields\] AND "catheters"\[All Fields\]) OR "central venous catheters"\[All Fields\] OR ("central"\[All Fields\] AND "venous"\[All Fields\] AND "catheter"\[All Fields\]) OR "central venous catheter"\[All Fields\]) AND ("saline solution"\[MeSH Terms\] OR ("saline"\[All Fields\] AND "solution"\[All Fields\]) OR "saline solution"\[All Fields\] OR ("normal"\[All Fields\] AND "saline"\[All Fields\]) OR "normal saline"\[All Fields\]) AND ("2012/01/01"\[PDAT\] : "2018/12/31"\[PDAT\])
  ("central venous catheters"\[MeSH Terms\] OR ("central"\[All Fields\] AND "venous"\[All Fields\] AND "catheters"\[All Fields\]) OR "central venous catheters"\[All Fields\] OR ("central"\[All Fields\] AND "venous"\[All Fields\] AND "catheter"\[All Fields\]) OR "central venous catheter"\[All Fields\]) AND ("saline solution"\[MeSH Terms\] OR ("saline"\[All Fields\] AND "solution"\[All Fields\]) OR "saline solution"\[All Fields\] OR ("normal"\[All Fields\] AND "saline"\[All Fields\]) OR "normal saline"\[All Fields\]) AND ("heparin"\[MeSH Terms\] OR "heparin"\[All Fields\]) AND ("2012/01/01"\[PDAT\] : "2018/12/31"\[PDAT\])
  ("central venous catheters"\[MeSH Terms\] OR ("central"\[All Fields\] AND "venous"\[All Fields\] AND "catheters"\[All Fields\]) OR "central venous catheters"\[All Fields\] OR ("central"\[All Fields\] AND "venous"\[All Fields\] AND "catheter"\[All Fields\]) OR "central venous catheter"\[All Fields\]) AND ("saline solution"\[MeSH Terms\] OR ("saline"\[All Fields\] AND "solution"\[All Fields\]) OR "saline solution"\[All Fields\] OR ("normal"\[All Fields\] AND "saline"\[All Fields\]) OR "normal saline"\[All Fields\]) AND ("heparin"\[MeSH Terms\] OR "heparin"\[All Fields\]) AND patency\[All Fields\] AND ("2012/01/01"\[PDAT\] : "2018/12/31"\[PDAT\])
  CVC\[All Fields\] AND ("saline solution"\[MeSH Terms\] OR ("saline"\[All Fields\] AND "solution"\[All Fields\]) OR "saline solution"\[All Fields\] OR ("normal"\[All Fields\] AND "saline"\[All Fields\]) OR "normal saline"\[All Fields\]) AND ("heparin"\[MeSH Terms\] OR "heparin"\[All Fields\]) AND patency\[All Fields\] AND ("2012/01/01"\[PDAT\] : "2018/12/31"\[PDAT\])
  CVC\[All Fields\] AND ("saline solution"\[MeSH Terms\] OR ("saline"\[All Fields\] AND "solution"\[All Fields\]) OR "saline solution"\[All Fields\] OR "0 9 nacl"\[All Fields\]) AND ("heparin"\[MeSH Terms\] OR "heparin"\[All Fields\]) AND patency\[All Fields\] AND ("2012/01/01"\[PDAT\] : "2018/12/31"\[PDAT\])
  CVC\[All Fields\] AND ("saline solution"\[MeSH Terms\] OR ("saline"\[All Fields\] AND "solution"\[All Fields\]) OR "saline solution"\[All Fields\] OR "0 9 nacl"\[All Fields\]) AND ("heparin"\[MeSH Terms\] OR "heparin"\[All Fields\]) AND patancy\[All Fields\] AND RCT\[All Fields\] AND ("2012/01/01"\[PDAT\] : "2018/12/31"\[PDAT\]
  ("sodium chloride"\[MeSH Terms\] OR ("sodium"\[All Fields\] AND "chloride"\[All Fields\]) OR "sodium chloride"\[All Fields\]) AND ("heparin"\[MeSH Terms\] OR "heparin"\[All Fields\]) AND ("catheterisation"\[All Fields\] OR "catheterization"\[MeSH Terms\] OR "catheterization"\[All Fields\]) AND ("2012/01/01"\[PDAT\] : "2018/12/31"\[PDAT\])
  ("sodium chloride"\[MeSH Terms\] OR ("sodium"\[All Fields\] AND "chloride"\[All Fields\]) OR "sodium chloride"\[All Fields\]) AND ("heparin"\[MeSH Terms\] OR "heparin"\[All Fields\]) AND ("catheterisation"\[All Fields\] OR "catheterization"\[MeSH Terms\] OR "catheterization"\[All Fields\]) AND PATENCY\[All Fields\] AND ("2012/01/01"\[PDAT\] : "2018/12/31"\[PDAT\])
  ("sodium chloride"\[MeSH Terms\] OR ("sodium"\[All Fields\] AND "chloride"\[All Fields\]) OR "sodium chloride"\[All Fields\]) AND ("heparin"\[MeSH Terms\] OR "heparin"\[All Fields\]) AND ("catheterisation"\[All Fields\] OR "catheterization"\[MeSH Terms\] OR "catheterization"\[All Fields\]) AND PATENCY\[All Fields\] AND ("adult"\[MeSH Terms\] OR "adult"\[All Fields\] OR "adults"\[All Fields\]) AND ("2012/01/01"\[PDAT\] : "2018/12/31"\[PDAT\])
  ("sodium chloride"\[MeSH Terms\] OR ("sodium"\[All Fields\] AND "chloride"\[All Fields\]) OR "sodium chloride"\[All Fields\]) AND ("heparin"\[MeSH Terms\] OR "heparin"\[All Fields\]) AND (("catheterisation"\[All Fields\] OR "catheterization"\[MeSH Terms\] OR "catheterization"\[All Fields\]) AND PATENCY\[All Fields\]) AND ("2012/01/01"\[PDAT\] : "2018/12/31"\[PDAT\])
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

 {#sec1-6}

International Clinical Trials Registry Platform {#sec2-15}
-----------------------------------------------

125 records for 119 trials found for: Heparin AND Catheter7 records for 6 trials found for: Heparin AND cvc

Embase search {#sec1-7}
=============

1(**'central venous catheter'**/exp OR **'central venous catheter'** OR ((**'central'**/exp OR central) AND venous AND (**'catheter'**/exp OR catheter))) AND (**'heparin'**/exp OR heparin) AND (**'normal saline'**/exp OR **'normal saline'** OR (normal AND (**\'saline'**/exp OR saline))) 1752(**'central venous catheter'**/exp OR **'central venous catheter'** OR ((**'central'**/exp OR central) AND venous AND (**'catheter'**/exp OR catheter))) AND (**'heparin'**/exp OR heparin) AND (**'normal saline'**/exp OR **'normal saline'** OR (normal AND (**\'saline'**/exp OR saline))) AND patency 493(**'central venous catheter'**/exp OR **'central venous catheter'** OR ((**'central'**/exp OR central) AND venous AND (**'catheter'**/exp OR catheter))) AND (**'heparin'**/exp OR heparin) AND (**'normal saline'**/exp OR **'normal saline'** OR (normal AND (**\'saline'**/exp OR saline))) AND patency AND (**'adult'**/exp OR adult) 1894(**'heparin'**/exp OR heparin) AND (**'0.9** % **sodium chloride'** OR (0.9 AND % AND (**\'sodium'**/exp OR sodium) AND (**'chloride'**/exp OR chloride))) AND patency AND (**'adult'**/exp OR adult) 155(**'heparin'**/exp OR heparin) AND (**'0.9** % **sodium chloride'** OR (**0.9** AND % AND (**\'sodium'**/exp OR sodium) AND (**'chloride'**/exp OR chloride))) AND (**'occlusion'**/exp OR occlusion) AND (**'adult'**/exp OR adult) 146('heparin'/exp OR heparin) AND normal AND saline 9447('heparin'/exp OR heparin) AND normal AND saline AND central AND venous AND catheter 538('central'/exp OR central) AND venous AND ('catheter'/exp OR catheter) AND ('heparin'/exp OR heparin) AND normal AND (\'saline'/exp OR saline) AND patency 209('central'/exp OR central) AND venous AND ('catheter'/exp OR catheter) AND ('heparin'/exp OR heparin) AND normal AND (\'saline'/exp OR saline) AND patency AND adult 09
